You can blame your company's failed M&A attempt on hormones — young, male hormones, that is. According to research from Sauder School of Business, testosterone can be a negative factor in high-stakes decision making. Researchers found that young, male CEOs (who have higher levels of testosterone) tend to reject M&A offers even when it's against their interest — 20 percent more likely than their older male counterparts.